Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126922192 | 12692219 | 2 | F | 201608 | 20160908 | 20160828 | 20160912 | EXP | PHJP2016JP024002 | NOVARTIS | 0.00 | E | Y | 0.00000 | 20160912 | PH | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126922192 | 12692219 | 1 | PS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 4.6 MG QD PATCH 5 (CM2) | Y | 22083 | 4.6 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | |||||
| 126922192 | 12692219 | 2 | SS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 9.5 MG, QD (18 MG /EXELON 10 CM2 PATCH) | Y | 22083 | 9.5 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | |||||
| 126922192 | 12692219 | 3 | SS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 6.9 MG, QD PATCH 7.5(CM2) | Y | 22083 | 6.9 | MG | TRANS-THERAPEUTIC-SYSTEM | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126922192 | 12692219 | 1 | Dementia Alzheimer's type |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126922192 | 12692219 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126922192 | 12692219 | Pneumonia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |